News
Wednesday, May 22nd, 2019
Sirona Biochem Hires Contract Research Organization for Manufacturing Process Optimization for TFC-1067
Wednesday, May 15th, 2019
Sirona Biochem Receives Positive Clinical Results of its Skin Lightening Compound TFC-1067 from China
Wednesday, April 10th, 2019
Sirona Biochem’s TFC-1067 Demonstrates Superiority to Hydroquinone for the Treatment of Dyschromia
Wednesday, February 27th, 2019
Sirona Biochem Announces Close of Oversubscribed Private Placement
Tuesday, February 26th, 2019
Sirona Biochem to Exhibit at PCHi 2019 in Guangzhou China
Tuesday, February 26th, 2019
Sirona Biochem Announces Financing
Wednesday, February 13th, 2019
Sirona Biochem Advances Skin Lightener TFC-1067 Development and IP Protection in Anticipation of Licensing Discussions
Wednesday, February 6th, 2019
Sirona Biochem Receives Up-front Payment for Right of First Refusal Contract for Skin Lightener TFC-1067
Wednesday, January 30th, 2019
Sirona Biochem Releases CEO Letter to Shareholders – Clinical trial results expected Q1 2019
Tuesday, December 11th, 2018
Sirona Biochem’s SGLT2 Inhibitor in Testing for Animal Health
Product Development
While carbohydrate-based molecules offer immense commercial potential, we are focusing on three programs at this time.
Social Links Sidebar